News
MRNA
202.63
-17.57%
-43.18
Moderna, Meta, SpaceX, AT&T, CoreWeave, Sandisk, and More Stocks That Explain Today's Market
Barron‘s · 32m ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Merck & Company (MRK)
TipRanks · 56m ago
Moderna melanoma data fall short of highest expectations, says Citi
TipRanks · 1h ago
Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak
Barron‘s · 1h ago
Biggest stock movers Friday: SKHY, MRNA, DECK, and more
Seeking Alpha · 2h ago
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
TipRanks · 3h ago
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
Barchart · 5h ago
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
The Motley Fool · 14h ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Trevi Therapeutics (TRVI)
TipRanks · 14h ago
Moderna Stock Plunges 18% As Leaked Melanoma Vaccine Data Underperforms
NASDAQ · 14h ago
The top-performing S&P 500 stocks YTD have shed almost 7% on average
Seeking Alpha · 14h ago
Moderna Inc. Stock Falls 17.6%, Underperforms Peers
Dow Jones · 14h ago
Moderna selloff after data leak ‘a sell the news event,’ says Bernstein
TipRanks · 15h ago
Merck intismeran data concerns look ‘overdone,’ says Wells Fargo
TipRanks · 16h ago
Merck, Moderna say INTerpath-001 trial data demonstrates favorable OS trend
TipRanks · 16h ago
Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%
Benzinga · 16h ago
Moderna's Stock Plummet After Cancer-Vaccine Data Shared on Social Media -- Update
The Wall Street Journal · 16h ago
Moderna Stock Crashes 25% After Cancer-Vaccine Data Leak
Barron‘s · 16h ago
Moderna Stock Is Crashing Over 20%: What Spooked Investors and What Wall Street Sees Next
TipRanks · 16h ago
TD comments on ‘unsubstantiated’ melanoma data from Moderna
TipRanks · 16h ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).